Risk factors
PTC Therapeutics (PTCT) risk factors
Item 1A of every PTC Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors46 risks3 dropped12 reworded
Translarna’s EEA authorization risk was dropped, while stock-price disclosures now emphasize Sephience and country-specific Translarna access.
Filed Feb 19, 2026 - FY2024 10-K risk factors55 risks
Regulatory and commercialization risks dominate, especially Translarna’s EEA renewal and pricing or reimbursement for Translarna and Upstaza.
Filed Feb 27, 2025